Thanks to volunteers, SBCoA has played a role in many landmark discoveries, including debunking the theories that aluminum or mercury cause Alzheimer's, identifying so-called "AD mimics", and proving that there are changes in the brain decades before there are outward symptoms of AD.
A team of scientists have designed and tested a novel and promising therapeutic strategy for treating Lafora Disease (LD), a fatal form of childhood epilepsy.
Faculty from the Dept of Psychology in the College of Arts & Sciences and Behavioral Science in the College of Medicine have received two, five-year Research Project Grants from the NIH to study neurobehavioral processes involved in drug use disorders.
In this episode of "Behind the Blue," Sanders-Brown director Linda Van Eldik talks about the center's involvement in some of the most important discoveries in the history of Alzheimer's research and what they are doing now to advance the science.
In the past, using "Alzheimer’s disease" & "dementia" interchangeably was a generally accepted practice. Now there's rising appreciation that a variety of diseases & disease processes contribute to dementia.
Linda Van Eldik, director of the UK Sanders-Brown Center on Aging, received $5.5 million from NIH and the Alzheimer's Drug Discovery Foundation. She developed a drug that is ready for its first round of testing in humans.
It's an irrefutable fact that smoking is bad for you. Study after study has proven that smoking increases your risk for cancer, heart disease, diabetes – even blindness. But dementia? Not so fast. A recent study has demonstrated that smoking is not associated with a higher risk of dementia.
In an editorial published in CNS Spectrums, UK Neurologist Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).
Researchers at the University of Kentucky have discovered new biological processes by which mutations in the FUS gene cause neurodegeneration in amyotrophic lateral sclerosis (ALS).
Research from the Sanders-Brown Center on Aging presented at the Society for Neuroscience annual meeting has identified two potential ways to predict vascular cognitive impairment and dementia (VCID) – the second leading cause of dementia behind Alzheimer's disease.
